The nano-enhanced antibiotic effectively erradicates bacteria from lung cells (bottom line).
Novel nanotech improves cystic fibrosis antibiotic by 100,000-fold
World-first nanotechnology developed by the University of South Australia could change the lives of thousands of people living with cystic fibrosis (CF) as groundbreaking research shows it can improve the effectiveness of the CF antibiotic Tobramycin, increasing its efficacy by up to 100,000-fold.
The new technology uses a biomimetic nanostructured material to augment Tobramycin – the antibiotic prescribed to treat chronic Pseudomonas aeruginosa lung infections in severe cases of CF – eradicating the infection in as little as two doses.
In Australia, cystic fibrosis (CF) affects one in 2500 babies – or one baby born every four days – causing severe impairments to a person’s lungs, airways and digestive system, trapping bacteria and leading to recurrent infections. Lung failure is the major cause of death for people with CF.
The UniSA research team, which includes Professor Clive Prestidge, Dr Nicky Thomas, and PhD candidate, Chelsea Thorn, says the discovery could transform the lives of people living with CF.
“CF is a progressive, genetic disease that causes persistent, chronic lung infections and limits a person’s ability to breathe,” Thorn says.
“The disease causes thick, sticky mucus to clog a person’s airways, attracting germs and bacteria, such as Pseudomonas aeruginosa, which leads to recurring infections and blockages.
“Tobramycin is commonly used to treat these infections but increasingly antibiotics are failing to make any significant difference to lung infections, leaving sufferers requiring life-long antibiotic therapy administered every month.
“Our research successfully treats advanced human cell culture lung infections using nano-enhanced Tobramycin and shows how it can eradicate serious and persistent infections after only two doses.
“This could be a real game-changer for people living with CF.”
Researchers enhanced the Tobramycin with a biometric, nanostructured, lipid liquid crystal nanoparticle (LCNP)-based material, testing it on a new lung infection model to showcase its unique ability to penetrate the dense surface of the bacteria and kill the infection.
Dr Nicky Thomas, who is supported by a Mid-Career Fellowship from The Hospital Research Foundation Group, says the discovery continues the global battle to eradicate and prevent Pseudomonas aeruginosa.
Tobramycin works by inhibiting the synthesis of bacteria and causing cell membrane damage. Yet, as it’s a concentration-dependent antibiotic, achieving a sufficiently high concentration is critical,” Dr Thomas says.
“Our technology improves the performance of Tobramycin without increasing the toxicity of the drug, so what we’re doing is a far more effective and efficient treatment for chronic lung infections.”
The technology is currently entering pre-clinical trials and hopes to be on the market in the next five years.
Original Article: Novel nanotech improves cystic fibrosis antibiotic by 100,000-fold
More from: University of South Australia
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Nano-enhanced Tobramycin
- Extend Life Expectancy Against Aggressive Brain Cancers - Nano-Cap Firm Biodexa's Investigational Drug Shows Potential
Biodexa Pharmaceuticals (NASDAQ:BDRX), developing MTX110 for Diffuse Midline Glioma (DMG) in pediatric patients and for Recurrent Glioblastoma (rGBM) in adults, says early trials of MTX110 in both ...
- Nano Labs Announces Second Half of 2023 Financial Results
HANGZHOU, China, March 18, 2024 (GLOBE NEWSWIRE) -- Nano Labs Ltd (Nasdaq ... and we anticipate the launch of enhanced versions of our products in 2024, which are expected to deliver substantially ...
- Nanoparticles turbocharge turmeric's curcumin for enhanced health benefits
By Dr. Sanchari Sinha Dutta, Ph.D. A review article published in the journal Antioxidants provides a detailed overview of nanoparticle-based strategies to improve the bioavailability and bioactivity ...
Go deeper with Google Headlines on:
Nano-enhanced Tobramycin
[google_news title=”” keyword=”nano-enhanced Tobramycin” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Nano-enhanced drugs
- Extend Life Expectancy Against Aggressive Brain Cancers - Nano-Cap Firm Biodexa's Investigational Drug Shows Potential
Biodexa Pharmaceuticals (NASDAQ:BDRX), developing MTX110 for Diffuse Midline Glioma (DMG) in pediatric patients and for Recurrent Glioblastoma (rGBM) in adults, says early trials of MTX110 in both ...
- Nano-Chemicals Market Segmentation Synergy Enhancing Strategies for Effective Market Targeting
This market report is an excellent fusion of qualitative and quantitative data emphasizing major industry changes, business and competitor difficulties in gap analysis, and potential new possibilities ...
- Researchers create biocompatible nanoparticles to enhance systemic delivery of cancer immunotherapy
Researchers are enhancing immunotherapy effects against malignant tumors by developing and validating patent-ending poly (lactic-co-glycolic acid), or PLGA, nanoparticles modified with adenosine ...
- North America Nanotechnology Drug Delivery Market Exhibits 8.1% CAGR, Fueled by Advancements in Precision Medicine
The "North America Nanotechnology Drug Delivery Market Size, Share & Trends Analysis Report By Formulation (Polymer-Based Nanomedicine, Lipid-Based Nanomedicine, Nanocrystals, and Others), By ...
- Silk peptide nanoparticles show promise for enhancing targeted cancer therapy through dual-drug delivery
Building on this foundation, researchers from Wuhan University and Anhui Medical University in China have developed a unique drug delivery system using silk peptide nanoparticles. As reported in the ...
Go deeper with Google Headlines on:
Nano-enhanced drugs
[google_news title=”” keyword=”nano-enhanced drugs” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]